OGN - Organon Q3 2021 Earnings Preview

Organon (NYSE:OGN) is scheduled to announce Q3 earnings results on Thursday, November 11th, before market open. The consensus EPS Estimate is $1.44 and the consensus Revenue Estimate is $1.59B. Organon shares traded ~4% higher after the company swung back to growth with better than expected financials for Q2 2021, in August. Seeking Alpha contributor Gen Alpha argued that Organon "is an irresistible bargain", and said that the company has shown disappointing share price performance since being spun-off from Merck. The company received clearance by the U.S. FDA of the Special 510(k) for technological updates to the company's Jada System, in October. Recently, CFRA had initiated shares of Organon with a hold rating and a $34 price target (~4% upside). Over the last 3 months, EPS estimates have seen 2 upward revisions and 2 downward. Revenue estimates have seen 1 upward revision and 1 downward.

For further details see:

Organon Q3 2021 Earnings Preview